Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Senior Reporter

Eli Lilly has tapped another gene editing partner, this time looking to go after a large patient population in the cardiovascular space with the help …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing